THERAMEX
23.12.2021 15:08:08 CET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1 .
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil , Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 09:32:00 CEST | Press release
The EU-funded project brings policymakers, industry and cities together to discuss how circular economy solutions can scale beyond pilots. The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo31.3.2026 09:00:00 CEST | Press release
Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C Redoxblox, a leader in thermochemical energy storage (TCES) on a mission to electrify the world with technology that shifts the power dynamic, today announced its rebrand to Tempo. The new identity marks the company’s transition from technology development to the commercial scaling of its breakthrough electrified heat platform. The rebrand, developed in partnership with renowned creative agency Red Antler, aligns Tempo’s strategic identity with its unique ability to meet the rigorous demands of heavy industry. The name Tempo is a nod to three core pillars of the company’s value proposition: Temperature leadership, the time-shifting of energy, and the pace of both continuous industrial heat delivery and rapid innovation. “As we move from technical validation toward large-scale commercial rollout, our brand must reflect the scale of the challenge we
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management31.3.2026 09:00:00 CEST | Press release
Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares' platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on a powerful rules engine that enables intuitive compensation plan design, giving organizations the flexibility to model incentive structures in a fully self-service environment, unlocking new possibilities for incentive management at scale. Supporting more than 40 organizations, including Nespresso, TheFork, and Rakuten, Amalia provides real-time visibility into performance and incentive data, enabling companies to operate complex compensation programs with greater control and efficiency. “From day one, our focus has been to bring clarity to performance-based comp
Schneider Electric Joins Thread Group Board of Directors31.3.2026 09:00:00 CEST | Press release
Global technology leader elevates its membership to drive the future of smart homes and commercial buildings The Thread Group, an industry alliance addressing IoT convergence, security, power, and architecture challenges, today announced that Schneider Electric has joined its Board of Directors. A member of the Thread Group since 2015, Schneider Electric will take a more active role in shaping the future of the Thread wireless networking protocol moving forward. This addition comes at a pivotal time for the organization, with Thread recently surpassing 1000 consumer products, and as we continue to see expansion into commercial markets. Thread 1.4 delivers significant benefits for commercial and industrial applications, including seamless communication, enhanced reliability, and performance in expansive IoT deployments. "The entire Thread Group will benefit from Schneider Electric’s deeper engagement in our efforts," said Vividh Siddha, President of Thread Group. "A dedicated member for
STV Group and Post-Quantum Successfully Trial World’s First Quantum-Resilient Drones31.3.2026 09:00:00 CEST | Press release
Partnership delivers quantum-resilient drone platform for NATO allies Technical breakthrough: first airborne deployment of Classic McEliece algorithm Combat-proven UAV systems integrated with Classic McEliece post-quantum cryptography (PQC) to secure unmanned operations against future quantum threats. STV Group a.s., a European defence technology integrator with platforms deployed in Ukraine and allied theatres, and Post-Quantum, the UK cybersecurity company, today announced successful testing of the world’s first quantum-safe drones for active deployment across allied theatres. As allied nations adapt to warfighting defined by autonomous systems and drones, the ability to futureproof secure communications between drones and their operators is of paramount importance. Drone swarms procured today may be stored and deployed in future operations years later. This dynamic requires drones manufactured today incorporate encryption that’s resistant to attack by both classical and quantum comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom